Downregulation of the hexokinase II gene sensitizes human colon cancer cells to 5-fluorouracil

Chemotherapy

Volumn 54, Issue 5, 2008, Pages 357-363

  Peng, Qiu Ping ^a,b   Zhou, Jin Ming ^a   Zhou, Qi ^a   Pan, Feng ^a   Zhong, Da Ping ^a   Liang, Hou Jie ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b The 94th Hospital of PLA   (China)

Author keywords

5 Fluorouracil; Apoptosis; Colorectal cancer; Drug resistance; Glycolysis; Hexokinase; RNA interference; Thymidylate synthase

Indexed keywords

CASPASE 3; FLUOROURACIL; HEXOKINASE; THYMIDYLATE SYNTHASE;

APOPTOSIS; ARTICLE; CANCER CELL; CHEMOSENSITIVITY; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GLYCOLYSIS; HUMAN; HUMAN CELL; IC 50; MITOCHONDRIAL MEMBRANE POTENTIAL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA INTERFERENCE;

APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOWN-REGULATION; ENZYME ACTIVATION; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEXOKINASE; HUMANS; MATRIX METALLOPROTEINASES; RNA INTERFERENCE;

EID: 50849103321     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000153655     Document Type: Article

References (29)

1. Sobrero AF, Aschele C, Bertino JR: Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation. J Clin Oncol 1997;15:368-381.
2. 0-ATP synthase in human colon cancer cells with induced 5-fluorouracil resistance. Cancer Res 2005;65:3162-3170.
3. Warburg O: On the origin of cancer cells. Science 1956;123:309-314.
4. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, Keating MJ, Huang P: Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005;65:613-621.
5. Pastorino JG, Hoek JB, Shulga N: Activation of glycogen synthase kinase 3β disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res 2005;64:10545-10554.
6. Peng QP, Liang HJ, Zhou Q, Zhou JM, Fu XL, Zhong DP: Expression of the hexokinase-II gene in human colon cancer cells and the therapeutic significance of inhibition thereof (in Chinese). Zhonghua Yi Xue Za Zhi 2007;87:1058-1062.
7. Pelicano H, Martin DS, Xu RH, Huang P: Glycolysis inhibition for anticancer treatment. Oncogene 2006;25:4633-4646.
8. Mathupala SP, Ko YH, Pedersen PL: Hexokinase II: cancer's double-edged sword acting as both facilitator and gate keeper of malignancy when bound to mitochondria. Oncogene 2006;25:4777-4786.
9. Sui D, Wilson JE: Selective depletion of the type I, type II, and type III isozymes of hexokinase in mammalian cells using small interfering RNAs. Biochem Biophys Res Commun 2004;319:768-773.
10. Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 2002;296:550-553.
11. Paul CP, Good PD, Winer I, Engelke DR: Effective expression of small interfering RNA in human cells. Nat Biotechnol 2002;20:505-508.
12. Schubert A, Grimm SS: Cyclophilin D, a component of the permeability transitionpore, is an apoptosis repressor. Cancer Res 2004;64:85-93.
13. Giagkousiklidis S, Vellanki SH, Debatin KM, Fulda S: Sensitization of pancreatic carcinoma cells for gamma-irradiation-induced apoptosis by XIAP inhibition. Oncogene 2007;26:7006-7016.
14. Garber K: Energy deregulation: licensing tumors to grow. Science 2006;312:1158-1159.
15. Airley RE, Mobasheri A: Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy 2007;53:233-256.
16. Gwak GY, Yoon JH, Kim KM, Lee HS, Chung JW, Gores GJ: Hypoxia stimulates proliferation of human hepatoma cells through the induction of hexokinase II expression. J Hepatol 2005;42:358-364.
17. Pedersen PL, Mathupala S, Rempel A, Geschwind JF, Ko YH: Mitochondrial bound type II hexokinase. Biochim Biophys Acta 2002;1555:14-20.
18. Robey RB, Hay N: Mitochondrial hexokinases: guardians of the mitochondria. Cell Cycle 2005;4:654-658.
19. Gatenby RA, Gillies RJ: Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol 2007;39:1358-1366.
20. Chen Z, Lu W, Garcia-Prieto C, Huang P: The Warburg effect and its cancer therapeutic implications. J Bioenerg Biomembr 2007;39:267-274.
21. Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, Saavedra E: Energy metabolism in tumor cells. FEBS J 2007;274:1393-1418.
22. Chang JM, Chung JW, Jae HJ, Eh H, Son KR, Lee KC, Park JH: Local toxicity of hepatic arterial infusion of hexokinase II inhibitor, 3-bromopyruvate: in vivo investigation in normal rabbit model. Acad Radiol 2007;14:85-92.
23. Huerta S, Goulet EJ, Livingston EH: Colon cancer and apoptosis. Am J Surg 2006;191:517-526.
24. Pedersen PL: Warburg, me and hexokinase 2: multiple discoveries of key molecular events underlying one of cancers' most common phenotypes, the 'Warburg effect', i.e., elevated glycolysis in the presence of oxygen. J Bioenerg Biomembr 2007;39:211-222.
25. Majewski N, Nogueira V, Robey RB, Hay N: Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol Cell Biol 2004;24:730-740.
26. Majewski N, Nogueira V, Bhaskar P, Coy PE, Skeen JE, Gottlob K, Chandel NS, Thompson CB, Robey RB, Hay N: Hexokinase mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol Cell 2004;16:819-830.
27. Kim W, Yoon JH, Jeong JM, Cheon GJ, Lee TS, Yang JI, Park SC, Lee HS: Apoptosis-inducing antitumor efficacy of hexokinase II inhibitor in hepatocellular carcinoma. Mol Cancer Ther 2007;6:2554-2562.
28. Rahman L, Voeller D, Rahman M, Lipkowitz S, Allegra C, Barrett JC, Kaye FJ, Zajac-Kaye M: Thymidylate synthase as an oncogene: a novel role for an essential DNA synthesis enzyme. Cancer Cell 2004;5:341-351.
29. Matsusaka S, Yamasaki H, Fukushima M, Wakabayashi I: Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer. Chemotherapy 2007;53:36-41.